AP2490A - Therapeutic compositions and the use thereof - Google Patents

Therapeutic compositions and the use thereof

Info

Publication number
AP2490A
AP2490A AP2009005083A AP2009005083A AP2490A AP 2490 A AP2490 A AP 2490A AP 2009005083 A AP2009005083 A AP 2009005083A AP 2009005083 A AP2009005083 A AP 2009005083A AP 2490 A AP2490 A AP 2490A
Authority
AP
ARIPO
Prior art keywords
therapeutic compositions
therapeutic
compositions
Prior art date
Application number
AP2009005083A
Other languages
English (en)
Other versions
AP2009005083A0 (en
Inventor
Brian P Kearney
Anita A Mathias
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2009005083A0 publication Critical patent/AP2009005083A0/en
Application granted granted Critical
Publication of AP2490A publication Critical patent/AP2490A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2009005083A 2007-06-29 2008-06-26 Therapeutic compositions and the use thereof AP2490A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94732507P 2007-06-29 2007-06-29
PCT/US2008/068351 WO2009006203A1 (en) 2007-06-29 2008-06-26 Therapeutic compositions and the use thereof

Publications (2)

Publication Number Publication Date
AP2009005083A0 AP2009005083A0 (en) 2009-12-31
AP2490A true AP2490A (en) 2012-10-04

Family

ID=39817166

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2009005083A AP2490A (en) 2007-06-29 2008-06-26 Therapeutic compositions and the use thereof

Country Status (21)

Country Link
US (4) US20110009411A1 (ja)
EP (1) EP2167089A1 (ja)
JP (3) JP5547067B2 (ja)
KR (1) KR20100028656A (ja)
CN (2) CN103356622A (ja)
AP (1) AP2490A (ja)
AR (1) AR067184A1 (ja)
AU (1) AU2008270634B2 (ja)
BR (1) BRPI0813955A2 (ja)
CA (1) CA2691736A1 (ja)
CO (1) CO6251236A2 (ja)
EA (1) EA200971096A1 (ja)
EC (1) ECSP109889A (ja)
IL (1) IL202745A0 (ja)
MX (1) MX2009013828A (ja)
NZ (1) NZ582089A (ja)
SG (1) SG182228A1 (ja)
TW (1) TW200916103A (ja)
UA (1) UA103881C2 (ja)
WO (1) WO2009006203A1 (ja)
ZA (1) ZA201000468B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2635468C (en) * 2005-12-30 2016-08-09 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
NZ573060A (en) 2006-07-07 2012-02-24 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
BRPI0716752A2 (pt) 2006-09-12 2013-09-17 Gilead Sciences Inc processo e intermediÁrios para preparo de inibidores de intergrase
HUE029842T2 (en) * 2007-02-23 2017-04-28 Gilead Sciences Inc Modulation of pharmacokinetic parameters of therapeutic agents
AP2965A (en) * 2007-06-29 2014-09-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
PL2296633T3 (pl) 2008-05-02 2016-03-31 Gilead Sciences Inc Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego
EP2555757B1 (en) * 2010-04-09 2016-05-25 Bristol-Myers Squibb Holdings Ireland Atazanavir sulfate formulations with improved ph effect
WO2012088178A1 (en) * 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
AU2012345732B2 (en) 2011-11-30 2016-07-14 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
CA2865491A1 (en) * 2012-03-01 2013-09-06 Gilead Sciences, Inc. Spray dried formulations
EP2880017B1 (en) 2012-08-03 2016-10-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
KR102406288B1 (ko) 2012-12-21 2022-06-13 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
ES2859102T3 (es) 2013-07-12 2021-10-01 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
NO2865735T3 (ja) 2013-07-12 2018-07-21
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (ja) 2014-06-20 2018-06-23
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CN107427529A (zh) 2014-12-26 2017-12-01 埃莫里大学 N4‑羟基胞苷和衍生物及与其相关的抗病毒用途
BR112017020837A2 (pt) 2015-04-02 2018-07-03 Gilead Sciences, Inc. compostos de carbamoilpiridona policíclicos e seu uso farmacêutico
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034001A1 (en) * 2003-10-09 2005-04-14 Steven Wheeler Adaptive medical decision support system
WO2005113508A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Stable crystal of 4-oxoquinoline compound
WO2007079260A1 (en) * 2005-12-30 2007-07-12 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
TR200401663T1 (tr) * 2002-11-20 2005-04-21 Japan Tobacco Inc. 4-oksokuinolin bileşiği ve bunun HIV integraz inhibitörü olarak kullanımı.
JP4629104B2 (ja) * 2004-05-21 2011-02-09 日本たばこ産業株式会社 ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤
US20060058286A1 (en) * 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
NZ573060A (en) * 2006-07-07 2012-02-24 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
BRPI0716752A2 (pt) * 2006-09-12 2013-09-17 Gilead Sciences Inc processo e intermediÁrios para preparo de inibidores de intergrase
AP2965A (en) * 2007-06-29 2014-09-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
PL2296633T3 (pl) * 2008-05-02 2016-03-31 Gilead Sciences Inc Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego
US20110000941A1 (en) * 2009-07-06 2011-01-06 Volk J Patrick Apparatus and System for Carrying a Digital Media Player

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034001A1 (en) * 2003-10-09 2005-04-14 Steven Wheeler Adaptive medical decision support system
WO2005113508A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Stable crystal of 4-oxoquinoline compound
WO2007079260A1 (en) * 2005-12-30 2007-07-12 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors

Also Published As

Publication number Publication date
US20090093482A1 (en) 2009-04-09
SG182228A1 (en) 2012-07-30
MX2009013828A (es) 2010-03-10
KR20100028656A (ko) 2010-03-12
US20170136000A1 (en) 2017-05-18
CO6251236A2 (es) 2011-02-21
AR067184A1 (es) 2009-09-30
EA200971096A1 (ru) 2010-08-30
CA2691736A1 (en) 2009-01-08
AU2008270634A1 (en) 2009-01-08
JP5547067B2 (ja) 2014-07-09
CN101743004A (zh) 2010-06-16
US20110009411A1 (en) 2011-01-13
BRPI0813955A2 (pt) 2017-05-09
UA103881C2 (ru) 2013-12-10
TW200916103A (en) 2009-04-16
US20140343062A1 (en) 2014-11-20
AU2008270634B2 (en) 2014-01-16
JP2015143277A (ja) 2015-08-06
ECSP109889A (es) 2010-03-31
WO2009006203A1 (en) 2009-01-08
NZ582089A (en) 2013-01-25
JP2010532373A (ja) 2010-10-07
EP2167089A1 (en) 2010-03-31
IL202745A0 (en) 2010-06-30
CN103356622A (zh) 2013-10-23
ZA201000468B (en) 2011-06-29
JP2013199494A (ja) 2013-10-03
JP5769762B2 (ja) 2015-08-26
AP2009005083A0 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
AP2965A (en) Therapeutic compositions and the use thereof
AP2490A (en) Therapeutic compositions and the use thereof
GB0719803D0 (en) Therapeutic compounds and their use
GB0719644D0 (en) Therapeutic compounds and their use
GB0625659D0 (en) Therapeutic compounds and their use
GB0701426D0 (en) Compounds and their use
HK1130489A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
HK1131922A1 (en) Phenylpropionamide compounds and the use thereof
GB0724251D0 (en) Therapeutic compounds and their use
IL202073A0 (en) Substituted oxazolidinones and the use thereof
GB0722680D0 (en) Therapeutic compounds and their use
EP2307052A4 (en) ANTI-BETA-2-MICROGLOBULIN AGENTS AND THEIR USE
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
EP2133326A4 (en) NEW PSEUDOGLYCOLIPID AND ITS USE
EP2231163A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USE
GB0808690D0 (en) Therapeutic use
GB0714500D0 (en) composition and treatment
GB0608797D0 (en) Novel agents and the use thereof
GB0705517D0 (en) Therapeutic compounds and their use
ZA201000469B (en) Therapeutic compositions and the use thereof
GB0614538D0 (en) Therapeutic Compounds And Their Use
GB0711465D0 (en) Silan-3-amines and disilan-5-amines as therapeutic agents
GB0720518D0 (en) Compositions and their use
GB0720524D0 (en) Compositions and their use
GB0711036D0 (en) Composition and their use